Covered recipient · General Payments record
JACKIE WISZCZUR
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,458.62
- Reported across 93 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $374.20 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sumitomo Pharma America, Inc. | $86.88 | 3 |
| ABBVIE INC. | $50.30 | 2 |
| UROGEN PHARMA, INC. | $46.65 | 3 |
| COLOPLAST CORP | $41.14 | 2 |
| DENTSPLY IH AB | $31.91 | 1 |
| Tempus AI, Inc | $29.66 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $27.69 | 1 |
| TOLMAR, INC. | $24.25 | 1 |
| Janssen Biotech, Inc. | $20.74 | 1 |
| 180 Medical, Inc. | $14.98 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| 180 Medical, Inc. | $14.98 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151369271 | CMS |
| ABBVIE INC. | $21.73 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108429784 | CMS |
| ABBVIE INC. | $28.57 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108429786 | CMS |
| COLOPLAST CORP | $21.86 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117457016 | CMS |
| COLOPLAST CORP | $19.28 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117457082 | CMS |
| DENTSPLY IH AB | $31.91 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131730315 | CMS |
| Janssen Biotech, Inc. | $20.74 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078570913 | CMS |
| Novartis Pharmaceuticals Corporation | $27.69 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087349534 | CMS |
| Sumitomo Pharma America, Inc. | $26.71 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149005005 | CMS |
| Sumitomo Pharma America, Inc. | $30.27 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149005007 | CMS |
| Sumitomo Pharma America, Inc. | $29.90 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149005009 | CMS |
| Tempus AI, Inc | $29.66 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150188922 | CMS |
| Tolmar, Inc. | $24.25 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138707469 | CMS |
| UROGEN PHARMA, INC. | $15.49 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137931194 | CMS |
| UROGEN PHARMA, INC. | $15.64 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137922989 | CMS |
| UROGEN PHARMA, INC. | $15.52 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137927914 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.